At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
ARGX-113 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
In Brief
A Phase 2 clinical trial evaluating ARGX-113 and Placebo for Myasthenia Gravis. Completed, enrolled 24 participants across 19 sites in 8 countries.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, multicenter Phase II study to evaluate the safety, efficacy, and pharmacokinetics of ARGX-113 for the treatment of autoimmune Myasthenia Gravis (MG) with generalized muscle weakness.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyasthenia Gravis
CountriesBelgium, Canada, Italy, Netherlands, Poland, Spain, Sweden, United States
CollaboratorsQuintiles, Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionOct 2017
TodayJul 2026
First PostedNov 17, 2016
Enrollment StartDec 30, 2016
Primary CompletionOct 20, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.6 years ago
Interventions
ARGX-113biological
Placebodrug